Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
As of March 2024, there are more than 16 compounds being developed by 11 different companies in late-stage development (phase II or III), an additional 18 compounds in phase I, and approximately 40 in pre-phase I development
Its part of the broader category of IGF-1 peptide therapy, which is gaining attention in the anti-aging and performance fields
It's creating entirely new purchase priorities and exposing category adjacencies no one was modeling
This growth is driven by demand for glucose-modulating blends that balance protein, fiber, and fat to support satiety and treatment outcomes
You might notice those initial side effects becoming less intense or even disappearing altogether
A 300% increase from a very low baseline is still a very low number
US$ 26.94
US$ 21.52
US$ 29.87
